Histone Methylation Modification Patterns and Relevant M-RiskScore in Acute Myeloid Leukemia

Overview

Journal Heliyon

Specialty Social Sciences

Date 2022 Sep 27

PMID 36164519

Authors

Dade Rong

Xiaomin Chen

Jing Xiao

Daiyuan Liu

Xiangna Ni

Xiuzhen Tong

Haihe Wang

Affiliations

Soon will be listed here.

Abstract

Objective: We tried to identify novel molecular subtypes of acute myeloid leukemia (AML) associated with histone methylation and established a relevant scoring system to predict treatment response and prognosis of AML.

Methods: Gene expression data and clinical characteristics of patients with AML were obtained from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database. Molecular subtyping was carried out by consensus clustering analysis, based on the expression of 24 histone methylation modification regulators (HMMRs). The clinical and biological features of each clustered pattern were taken into account. The scoring system was constructed by using differential expression analysis, Cox regression method and lasso regression analysis. Subsequently, the scoring system in the roles of prognostic and chemotherapeutic prediction of AML were explored. Finally, an independent GSE dataset was used for validating the established clustering system.

Results: Two distinct subtypes of AML were identified based on the expression of the 24 HMMRs, which exhibited remarkable differences in several clinical and biological characteristics, including HMMRs expression, AML-M0 distribution, mutation, tumor mutation burden, somatic mutations, pathway activation, immune cell infiltration and patient survival. The scoring system, M-RiskScore, was established. Integrated analysis demonstrated that patients with the low M-RiskScore displayed a prominent survival advantage and a good response to decitabine treatment, while patients with high M-RiskScore have resistance to decitabine, but they could benefit from IA regimen therapy.

Conclusion: Detection of HMMRs expression would be a potential strategy for AML subtyping. Meanwhile, targeting histone methylation would be a preferred strategy for either AML-M0 or mutant patients. M-RiskScore was a useful prognostic biomarker and a guide for the choice of appropriate chemotherapy strategy.

Citing Articles

Immunotherapy-relevance of a candidate prognostic score for Acute Myeloid Leukemia.

Pan Y, Zeng W, Nie X, Chen H, Xie C, Guo S Heliyon. 2024; 10(11):e32154.

PMID: 38961904 PMC: 11219318. DOI: 10.1016/j.heliyon.2024.e32154.

Comprehensive characterization of immunogenic cell death in acute myeloid leukemia revealing the association with prognosis and tumor immune microenvironment.

Chen Y, Qiu X, Liu R BMC Med Genomics. 2024; 17(1):107.

PMID: 38671491 PMC: 11046942. DOI: 10.1186/s12920-024-01876-w.

References

Moslehi J, Deininger M . Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015; 33(35):4210-8. PMC: 4658454. DOI: 10.1200/JCO.2015.62.4718. View

Fiskus W, Sharma S, Shah B, Portier B, Devaraj S, Liu K . Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014; 28(11):2155-64. PMC: 4739780. DOI: 10.1038/leu.2014.119. View

Salvatori B, Iosue I, Damas N, Mangiavacchi A, Chiaretti S, Messina M . Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. Genes Cancer. 2011; 2(5):585-92. PMC: 3161419. DOI: 10.1177/1947601911416357. View

Ayatollahi H, Shajiei A, Sadeghian M, Sheikhi M, Yazdandoust E, Ghazanfarpour M . Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review. Hematol Oncol Stem Cell Ther. 2016; 10(1):1-7. DOI: 10.1016/j.hemonc.2016.08.005. View

Wang H, Liu Y, Zhu C, Yan F, Wang M, Chen X . Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. J Exp Clin Cancer Res. 2020; 39(1):278. PMC: 7724824. DOI: 10.1186/s13046-020-01792-8. View

Prada-Arismendy J, Arroyave J, Rothlisberger S . Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2016; 31(1):63-76. DOI: 10.1016/j.blre.2016.08.005. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L . WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell. 2015; 57(4):662-673. PMC: 4336627. DOI: 10.1016/j.molcel.2014.12.023. View

10.

Mandrekar J . Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010; 5(9):1315-6. DOI: 10.1097/JTO.0b013e3181ec173d. View

11.

Fumet J, Truntzer C, Yarchoan M, Ghiringhelli F . Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. Eur J Cancer. 2020; 131:40-50. PMC: 9473693. DOI: 10.1016/j.ejca.2020.02.038. View

12.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

13.

Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm S . Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007; 13(11):3363-9. DOI: 10.1158/1078-0432.CCR-06-2667. View

14.

Jawhar M, Dohner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M . KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 2019; 33(5):1124-1134. PMC: 6756067. DOI: 10.1038/s41375-018-0346-z. View

15.

Cheung N, So C . Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett. 2011; 585(13):2100-11. DOI: 10.1016/j.febslet.2011.03.068. View

16.

Wouters B, Delwel R . Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2015; 127(1):42-52. DOI: 10.1182/blood-2015-07-604512. View

17.

de The H, Pandolfi P, Chen Z . Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer Cell. 2017; 32(5):552-560. DOI: 10.1016/j.ccell.2017.10.002. View

18.

Coombs C, Tallman M, Levine R . Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol. 2015; 13(5):305-18. PMC: 5525060. DOI: 10.1038/nrclinonc.2015.210. View

19.

Booken N, Gratchev A, Utikal J, Weiss C, Yu X, Qadoumi M . Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia. 2007; 22(2):393-9. DOI: 10.1038/sj.leu.2405044. View

20.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View